Autolus Therapeutics Liabilities 2024

Autolus Therapeutics Aktienanalyse

What does Autolus Therapeutics do?

Autolus Therapeutics PLC is a global biopharmaceutical company dedicated to the development of novel therapies for cancer. The company was founded in 2014 by an experienced team of scientists and executives from the biotech industry with the goal of revolutionizing cancer treatment. Autolus Therapeutics' business model is to develop and market novel cancer immunotherapies. The company utilizes innovative technologies such as CAR-T cell therapy and T-cell receptor (TCR) therapy. By targeting the immune system, cancer cells can be recognized and destroyed. Autolus Therapeutics operates a complex network of different sectors and areas to ensure comprehensive development and marketing of its products. This includes research and development, manufacturing and production, as well as clinical testing and approval of therapies. Currently, Autolus Therapeutics focuses on developing therapies for various types of cancer, such as leukemia, lymphoma, and solid tumors. The company has built a broad pipeline of products and therapeutic approaches that are currently in different phases of clinical development. The main focus is on an innovative CAR-T cell therapy, in which the body's own T cells are equipped with a chimeric antigen receptor (CAR) to specifically recognize and combat cancer cells. Autolus Therapeutics' different CAR-T therapies target specific antigens expressed on tumor cells. Another important part of Autolus Therapeutics' pipeline is T-cell receptor (TCR) therapies. T cells are equipped with specific receptors to also target and destroy cancer cells. These therapeutic approaches are currently in clinical development. Autolus Therapeutics collaborates closely with other companies and institutions in the industry to further advance the development and marketing of cancer therapies. This includes strategic partnerships with major pharmaceutical companies such as AstraZeneca and Bluebird Bio. The history of Autolus Therapeutics is characterized by rapid growth and high innovation. Shortly after its founding, the company was able to secure significant funding rounds and international partners. In the following years, the pipeline was further expanded, and the first clinical trials were initiated. Currently, Autolus Therapeutics employs over 250 people at locations in the United Kingdom and the United States. The company has a market capitalization of around $1.5 billion and is considered one of the most promising companies in the biopharmaceutical industry. In summary, Autolus Therapeutics is an innovative and ambitious company dedicated to the research and development of novel cancer therapies. The broad pipeline of products and therapeutic approaches, as well as the close partnerships in the industry, give hope for a promising future of the company. Autolus Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Autolus Therapeutics's Liabilities

Autolus Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Autolus Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Autolus Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Autolus Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Autolus Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Autolus Therapeutics stock

What is the level of liabilities of Autolus Therapeutics this year?

Autolus Therapeutics has a debt balance of 263.91 M USD this year.

What were the liabilities of Autolus Therapeutics compared to the previous year?

The liabilities of Autolus Therapeutics have increased by 37.74% increased compared to the previous year.

What are the consequences of high debt for investors of Autolus Therapeutics?

High liabilities can pose a risk for investors of Autolus Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Autolus Therapeutics?

Low liabilities mean that Autolus Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Autolus Therapeutics affect the company?

An increase in liabilities of Autolus Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Autolus Therapeutics affect the company?

A decrease in the liabilities of Autolus Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Autolus Therapeutics?

Some factors that can influence the liabilities of Autolus Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Autolus Therapeutics so important for investors?

The liabilities of Autolus Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Autolus Therapeutics take to modify the liabilities?

To change its liabilities, Autolus Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Autolus Therapeutics pay?

Over the past 12 months, Autolus Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Autolus Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Autolus Therapeutics?

The current dividend yield of Autolus Therapeutics is .

When does Autolus Therapeutics pay dividends?

Autolus Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Autolus Therapeutics?

Autolus Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Autolus Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Autolus Therapeutics located?

Autolus Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Autolus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Autolus Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Autolus Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Autolus Therapeutics in the year 2023?

In the year 2023, Autolus Therapeutics distributed 0 USD as dividends.

In which currency does Autolus Therapeutics pay out the dividend?

The dividends of Autolus Therapeutics are distributed in USD.